drugset / Trial / NCT02250170
Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Phase 1
Completed
47 enrolled
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This open-label, non-randomized trial will comprise of 2 parts. A dose escalation part will characterize the safety, biomarker and pharmacokinetics of OPB-111077 in advanced solid tumor. Subsequently, an expansion part will further evaluate the biomarker, safety, pharmacokinetics and antitumor activity of OPB-111077 in selected tumor types.
Timeline
- Start
- 2014-10-23
- Primary completion
- 2019-03-08
- Completion
- 2019-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPB-111077 | Small molecule | 300 mg | Oral |
| Subject | OPB-111077 | Small molecule | 500 mg | Oral |
| Subject | OPB-111077 | Small molecule | 700 mg | Oral |
| Subject | OPB-111077 | Small molecule | 900 mg | Oral |